Drugs / SIRPant-M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05967416 | Jan 2024 → Jun 2025 overdue | non-Hodgkin lymphoma | SIRPant Immunotherapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIRPant-M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05967416 ↗ |
| Known as | RB-1355 | “The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed...” NCT05967416 ↗ |
| Modality | Cell therapy | “SIRPant-M (RB-1355) , an autologous cell therapy” NCT05967416 ↗ |
| Route | Other | “given by intratumoral injection” NCT05967416 ↗ |